Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-case-based-guide-to-clinical-endocrinology-outpatient-management-of-yMPB3oGYUU
References (34)
-
M. Doumas, Κonstantinos Imprialos, K. Stavropoulos, Andromachi Reklou, A. Sachinidis, V. Athyros (2018)
Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.Current pharmaceutical design, 24 17
-
J. Zonszein, P. Groop (2016)
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseDiabetes Therapy, 7
-
M Hanefeld (2007)
20Cardiovasc Diabetol, 6
-
M. Powers, Joan Bardsley, M. Cypress, Paulina Duker, M. Funnell, Amy Fischl, M. Maryniuk, L. Siminerio, E. Vivian (2015)
Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and DieteticsDiabetes Care, 38
-
G. Viberti, S. Kahn, D. Greene, W. Herman, B. Zinman, R. Holman, S. Haffner, Daniel Levy, J. Lachin, Rhona Berry, M. Heise, N. Jones, M. Freed (2002)
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.Diabetes care, 25 10
-
P. Sarafidis, C. Ferro, E. Morales, A. Ortiz, J. Małyszko, R. Hojs, K. Khazim, R. Ekart, J. Valdivielso, D. Fouque, G. London, Z. Massy, P. Ruggenenti, E. Porrini, A. Wiecek, C. Zoccali, F. Mallamaci, M. Hornum (2019)
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTANephrology Dialysis Transplantation, 34
-
S. Prato (2009)
Megatrials in type 2 diabetes. From excitement to frustration?Diabetologia, 52
-
UKPDS Group (1998)
854Lancet, 352
-
P Gaede (2003)
383N Engl J Med, 348
-
(2007)
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes -
D. Drucker (2020)
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implicationsEndocrine Reviews
-
CC Quianzon (2012)
10J Commun Hosp Intern Med Perspect, 2
-
JJV McMurray (2019)
1995N Engl J Med, 381
-
CP Cannon (2020)
1425N Engl J Med, 383
-
M. Kalogirou, E. Sinakos (2018)
Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?World Journal of Hepatology, 10
-
WC Knowler (2002)
393N Engl J Med, 346
-
S. Heller, B. Bode, P. Kozlovski, A. Svendsen (2013)
Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitusJournal of Diabetes, 5
-
J. Rosenstock, V. Perkovic, O. Johansen, M. Cooper, S. Kahn, N. Marx, J. Alexander, M. Pencina, R. Toto, C. Wanner, B. Zinman, H. Woerle, David Baanstra, E. Pfarr, S. Schnaidt, T. Meinicke, J. George, M. Eynatten, D. McGuire (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical TrialJAMA, 321
-
M. Davies, D. D’Alessio, J. Fradkin, W. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D. Wexler, J. Buse (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care, 41
-
F. Cosentino, P. Grant, V. Aboyans, Clifford Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D. Grobbee, T. Hansen, H. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L. Mellbin, C. Östgren, B. Rocca, M. Roffi, N. Sattar, P. Seferovic, M. Sousa‐Uva, P. Valensi, D. Wheeler (2019)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.European heart journal
-
D. Leroith, G. Biessels, S. Braithwaite, F. Casanueva, B. Draznin, J. Halter, J. Halter, I. Hirsch, M. McDonnell, M. Molitch, M. Murad, A. Sinclair (2019)
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism, 104 5
-
J. Chun, Jodi Strong, S. Urquhart (2018)
Insulin Initiation and Titration in Patients With Type 2 DiabetesDiabetes Spectrum : A Publication of the American Diabetes Association, 32
-
V Perkovic (2019)
2295N Engl J Med, 380
-
MA Powers (2016)
70Clin Diabetes, 34
-
C. Cannon, Darren Mcguire, R. Pratley, S. Dagogo-Jack, J. Mancuso, S. Huyck, B. Charbonnel, W. Shih, Silvina Gallo, U. Masiukiewicz, G. Golm, F. Cosentino, Brett Lauring, S. Terra (2018)
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV)American Heart Journal, 206
-
A. Aminian, S. Nissen (2020)
Success (but Unfinished) Story of Metabolic SurgeryDiabetes Care, 43
-
TA Zelniker (2019)
31Lancet, 393
-
S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. Peters, A. Tsapas, R. Wender, D. Matthews (2014)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 38
-
J. Rosenstock, S. Kahn, O. Johansen, B. Zinman, M. Espeland, H. Woerle, E. Pfarr, A. Keller, M. Mattheus, David Baanstra, T. Meinicke, J. George, M. Eynatten, D. McGuire, N. Marx (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.JAMA
-
R. DeFronzo, S. Inzucchi, M. Abdul-Ghani, S. Nissen (2019)
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesDiabetes & Vascular Disease Research, 16
-
SM Dunlay (2019)
e294Circulation, 140
-
WN Kernan (2016)
1321N Engl J Med, 374
-
I. Kruglikov, P. Scherer (2020)
The Role of Adipocytes and Adipocyte‐Like Cells in the Severity of COVID‐19 InfectionsObesity (Silver Spring, Md.), 28
-
D. Patoulias, K. Stavropoulos, K. Imprialos, Alexandra Katsimardou, M. Kalogirou, K. Koutsampasopoulos, I. Zografou, C. Papadopoulos, A. Karagiannis, M. Doumas (2019)
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials.Diabetes research and clinical practice
- Publisher
- Springer International Publishing
- Copyright
- © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022
- ISBN
- 978-3-030-84366-3
- Pages
- 369 –385
- DOI
- 10.1007/978-3-030-84367-0_40
- Publisher site
- See Chapter on Publisher Site
Abstract
[Type 2 diabetes mellitus (T2DM) is a common chronic disease affecting an increasingly younger population and imposing a high burden and cost to the individual, healthcare system, and society as a whole. Prevention of the disease and attenuation of complications remain major goals of therapy. However, even when the disease can be easily diagnosed, efforts to prevent it have failed. Treatment consists of education, lifestyle changes for weight loss, and personalized pharmacotherapy tailored to each individual’s phenotype and comorbidities. We discuss how the use of appropriate regimens can lead to better adherence with decreased morbidity and mortality by preventing or diminishing diabetic complications.]
Published: Jan 4, 2022
Keywords: Type 2 diabetes mellitus (T2DM); Atherosclerotic cardiovascular disease (ASCVD); Cardiovascular outcomes trials (CVOTs); Major adverse cardiac events (MACE); Prevention; Cardiac; Renal